GLP-1 Medications and Your Kidneys: The FLOW Trial and the New Era of Kidney Protection

Table of Contents

1. Why Your Kidneys Matter More Than You Think
2. The Two Numbers That Track Kidney Health
3. The FLOW Trial: The Study That Changed Everything
4. Three Years of Kidney Function Preserved
5. The Evidence Before FLOW
6. The Meta-Analyses: 18,000 CKD Patients Confirm the Signal
7. How GLP-1 Medications Protect the Kidneys: Six Mechanisms
8. Can GLP-1 Medications Be Combined With SGLT2 Inhibitors?
9. What This Means for Patients With Kidney Disease

Chronic kidney disease is one of the most common and most dangerous complications of diabetes and obesity. It affects roughly one in three adults with diabetes. And for decades, there were very few tools to slow it down. The standard approach was blood pressure control with ACE inhibitors or ARBs, blood sugar management, and hoping for the best. Then SGLT2 inhibitors came along and showed real kidney protection. But now, GLP-1 medications have entered the picture with their own powerful kidney data. The landmark trial is called FLOW. And it changed the landscape of kidney disease treatment. This guide covers the FLOW trial in detail, the supporting evidence from prior trials, the six biological mechanisms behind kidney protection, the evidence for combining GLP-1 medications with SGLT2 inhibitors, and what all of this means for patients living with kidney disease.

Why Your Kidneys Matter More Than You Think

Your kidneys filter about 180 liters of blood every single day. They regulate blood pressure, balance electrolytes, remove waste products, and produce hormones that control red blood cell production and bone health. When kidneys start to fail, everything else follows. Heart disease accelerates. Anemia develops. Bones weaken. Fluid builds up. And eventually, patients end up on dialysis or needing a kidney transplant. Kidney disease is often called a "silent" condition because it produces no symptoms until it is advanced. By the time patients feel something is wrong, significant and often irreversible damage has already occurred. This is why early detection and early intervention matter so much. Diabetes and obesity are the two leading causes of chronic kidney disease in the United States. High blood sugar damages the tiny blood vessels inside the kidneys that do the filtering work. High blood pressure, which is common in both diabetes and obesity, compounds the damage. Over time, the kidneys lose their ability to filter effectively, and protein begins leaking into the urine.

The Two Numbers That Track Kidney Health

Two laboratory values are used to monitor kidney function:

• eGFR (estimated glomerular filtration rate) measures how well your kidneys are filtering blood. A normal eGFR is above 90. Below 60 indicates chronic kidney disease. Below 15 means kidney failure, and dialysis or transplant becomes necessary.
• UACR (urine albumin-to-creatinine ratio) measures how much protein is leaking into your urine. A normal UACR is below 30 mg/g. Between 30 and 300 is called moderately increased albuminuria (formerly "microalbuminuria"). Above 300 is severely increased albuminuria (formerly "macroalbuminuria"). The more protein leaking, the more damage is occurring.

When eGFR drops and UACR rises, the kidneys are in trouble. The goal of treatment is to slow the decline in eGFR and reduce the amount of protein leaking into the urine.

The FLOW Trial: The Study That Changed Everything

FLOW was the first dedicated kidney outcome trial for a GLP-1 medication. It was designed from the ground up to answer one question: can semaglutide protect the kidneys in patients who already have chronic kidney disease? The trial enrolled 3,533 patients with type 2 diabetes and established chronic kidney disease, meaning they already had reduced kidney function and significant protein leaking into their urine. Patients were randomized to receive semaglutide 1 mg weekly or placebo, on top of their standard care (which could include ACE inhibitors, ARBs, and SGLT2 inhibitors). The primary outcome was a composite of major kidney disease events: a 50 percent or greater drop in eGFR, kidney failure requiring dialysis or transplant, or death from kidney or cardiovascular causes. The results were so strong that the trial was stopped early by the independent data monitoring committee. Semaglutide reduced the primary outcome by 24 percent. The kidney-specific components alone were reduced by 21 percent. Cardiovascular death was reduced by 29 percent. And all-cause mortality was reduced by 20 percent. The number needed to treat was just 20. That means for every 20 patients treated with semaglutide over three years, one major kidney event was prevented. In clinical medicine, that is a remarkably efficient treatment. The benefits were consistent across all subgroups, including patients with more advanced CKD, patients with and without established cardiovascular disease, and patients who were already taking SGLT2 inhibitors.

Three Years of Kidney Function Preserved

Beyond the headline results, one number from the FLOW trial tells the story more powerfully than any other. The annual rate of eGFR decline, how fast the kidneys were losing function each year, was 1.16 milliliters per minute per 1.73 meters squared slower in the semaglutide group compared to placebo. That may sound like a small number, but over time it translates to roughly three extra years of kidney function preserved. Three years further from dialysis. Three years further from a transplant waiting list. Three years of independence. For patients watching their kidney numbers decline year after year, knowing that a medication can meaningfully slow that decline is not just statistically significant. It is life-changing.

The Evidence Before FLOW

FLOW did not come out of nowhere. The signals had been building for years across multiple major trials. The LEADER trial tested liraglutide in over 9,300 patients with type 2 diabetes and high cardiovascular risk. It showed a 22 percent reduction in a composite kidney outcome, driven primarily by a reduction in new-onset macroalbuminuria. SUSTAIN 6 tested injectable semaglutide in about 3,300 patients with type 2 diabetes and established cardiovascular or kidney disease. It demonstrated a 36 percent reduction in new or worsening nephropathy and nearly a 50 percent reduction in macroalbuminuria. The REWIND trial tested dulaglutide in over 9,900 patients with type 2 diabetes and showed a 15 percent reduction in a composite kidney outcome. A pooled analysis of LEADER and SUSTAIN 6, combining over 12,600 patients, confirmed that semaglutide and liraglutide lowered albuminuria by 24 percent versus placebo and significantly slowed eGFR decline. Critically, the kidney-protective effects were more pronounced in patients who already had CKD at baseline, exactly the patients who need protection most. Each of these trials was designed primarily to study cardiovascular outcomes, not kidney outcomes. The kidney findings were secondary analyses. FLOW was the first trial designed specifically to study kidney outcomes as the primary endpoint, and it confirmed what the earlier trials had suggested: GLP-1 medications genuinely protect the kidneys.

The Meta-Analyses: 18,000 CKD Patients Confirm the Signal

When individual trials are pooled together, the evidence becomes even more compelling. A 2025 meta-analysis focused specifically on patients with eGFR below 60, meaning patients with established chronic kidney disease. It included 12 trials and nearly 18,000 patients. The results confirmed that GLP-1 receptor agonists reduced the composite kidney outcome by 15 percent, reduced the risk of a 50 percent or greater eGFR decline by 28 percent, and lowered all-cause mortality by 23 percent. A 2026 meta-analysis expanded the analysis to 19 trials and over 90,000 patients. It confirmed a 19 percent reduction in the primary renal outcome, a 12 percent reduction in renal functional decline, and a 24 percent reduction in microalbuminuria. These are not marginal effects. These are clinically meaningful reductions in the events that lead to dialysis, transplant, and death.

How GLP-1 Medications Protect the Kidneys: Six Mechanisms

The kidney protection from GLP-1 medications is not just a side effect of better blood sugar. Mediation analyses from the LEADER and SUSTAIN 6 trials showed that improvements in blood sugar and blood pressure only explained about 10 to 25 percent of the kidney benefit. Something else is going on. Research has identified at least six direct mechanisms:

1. Direct tubular effects.

GLP-1 receptors are present on the cells of the kidney's proximal tubules. When activated, they inhibit a sodium transporter called NHE3, which promotes natriuresis, the excretion of sodium in the urine. This reduces sodium retention, lowers blood pressure, and may improve the pressure dynamics within the kidney itself. This is a direct effect on kidney tissue, independent of blood sugar.

2. Reduced inflammation.

GLP-1 medications reduce inflammatory markers like TNF-alpha, MCP-1, and NF-kB within the kidney. They convert inflammatory immune cells, including macrophages and T lymphocytes, into less inflammatory phenotypes. In animal models, this translates directly into less kidney inflammation and less fibrosis, which is the scarring that destroys kidney tissue over time. Since inflammation is a central driver of kidney disease progression, this mechanism may be one of the most important.

3. Reduced oxidative stress.

GLP-1 receptor activation increases protein kinase A activity, which inhibits NADPH oxidase, a major source of damaging free radicals in the kidney. Less oxidative stress means less damage to the delicate filtering structures called glomeruli.

4. Improved endothelial function.

GLP-1 receptors are present on the blood vessels within the kidney, including the juxtaglomerular apparatus. Activation improves nitric oxide production and blood flow regulation, protecting the tiny blood vessels that do the actual filtering work. Better blood flow means better filtration and less damage from abnormal pressure.

5. Reduced activation of the renin-angiotensin system (RAAS).

GLP-1 medications appear to dampen RAAS activity, which is one of the primary drivers of kidney damage in diabetes. This works alongside, not instead of, ACE inhibitors and ARBs. The two approaches target the same system through different pathways, providing complementary protection.

6. Reduced albuminuria.

Across every major trial, GLP-1 medications consistently and significantly reduce the amount of protein leaking into the urine. Albuminuria is not just a marker of kidney damage. It is a driver of further damage. Protein in the urine is toxic to the kidney tubules and triggers additional inflammation and fibrosis. Reducing albuminuria slows the entire cascade of progressive kidney injury. These six mechanisms explain why the kidney protection extends beyond what blood sugar improvement alone would predict. The medications are directly protecting kidney tissue through multiple simultaneous pathways.

Can GLP-1 Medications Be Combined With SGLT2 Inhibitors?

This is one of the most important clinical questions in kidney disease management right now. SGLT2 inhibitors like empagliflozin and dapagliflozin have their own proven kidney-protective effects through different mechanisms (primarily reducing intraglomerular pressure and improving tubuloglomerular feedback).

Can the two drug classes be used together?

The answer appears to be yes, and the benefits appear to be additive. In the FLOW trial, about 15 percent of patients were already on an SGLT2 inhibitor at baseline. Semaglutide's benefits on kidney outcomes, cardiovascular events, and mortality were consistent regardless of whether patients were also taking an SGLT2 inhibitor. There was no significant interaction between the two drug classes, meaning semaglutide worked just as well whether or not an SGLT2 inhibitor was on board. A 2025 meta-analysis confirmed that GLP-1 receptor agonist benefits on major cardiovascular events, cardiovascular death, all-cause mortality, heart failure hospitalization, and eGFR slope were all preserved in patients already on SGLT2 inhibitors, with no significant interaction. This suggests the two drug classes work through complementary mechanisms and their benefits stack on top of each other rather than overlapping. For patients with type 2 diabetes and chronic kidney disease, the combination of a GLP-1 receptor agonist plus an SGLT2 inhibitor, on top of an ACE inhibitor or ARB, represents the most comprehensive kidney protection strategy currently available.

What This Means for Patients With Kidney Disease

If you have type 2 diabetes and chronic kidney disease, the treatment landscape has fundamentally changed. A decade ago, the only proven kidney-protective medications were ACE inhibitors and ARBs. Today, there are three proven drug classes that protect the kidneys through different mechanisms:

• ACE inhibitors or ARBs, which block the renin-angiotensin system and reduce intraglomerular pressure.
• SGLT2 inhibitors, which reduce glucose reabsorption in the kidney, lower intraglomerular pressure through tubuloglomerular feedback, and reduce inflammation.
• GLP-1 receptor agonists, which protect the kidneys through at least six direct mechanisms including reduced inflammation, reduced oxidative stress, improved endothelial function, RAAS modulation, NHE3 inhibition, and albuminuria reduction.

The evidence supports using these drug classes together in appropriate patients. Each one adds a layer of protection that the others do not fully provide. If you are on a GLP-1 medication for weight loss or diabetes, your kidneys are getting protection that goes beyond what the scale or the blood sugar numbers show. And if you have early signs of kidney disease, such as rising UACR or declining eGFR, these medications may help preserve your kidney function for years longer than standard care alone. Talk to your doctor about whether your current treatment plan includes all three layers of kidney protection. For many patients, the answer is not yet, and that represents an opportunity.